VUMC News and Communications

(iStock)

Study to test combination therapy for breast cancer

Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

My Cancer Genome launches new search tool for clinical trials

Clinicians, investigators and cancer patients now have access to a new online search tool that provides more detailed information about clinical research trials available for cancer patients.

L-r: Maria Magdalena Campos-Pons, Heather Conner, Donna Y. Ford, Rhonda Y. Williams, D. Borden Lacy, Erik William Carter, Jeffrey L. Neul, Kevin M. Stack, Atsushi Inoue, Jonathan G. Schoenecker, Joni Hersch and Provost Susan R. Wente at the Oct. 23 endowed chair celebration. (John Russell/Vanderbilt)

Celebration honors 11 university endowed chair holders

Eleven Vanderbilt University faculty members named to endowed chairs were honored Oct. 23 during a festive celebration at the Student Life Center.

Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR-T therapy

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR-T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.

Ford Motor Company Fund and Community Services grant helps promote Teen Driver Safety Initiative at Monroe Carell Jr. Children’s Hospital at Vanderbilt

Heart Walk 2017

An estimated 8,000 participants enjoyed a sunny sky, warm temperature and live music during the 25th annual Greater Nashville Heart Walk on Saturday, Oct. 14.

1 164 165 166 167 168 391